Form 4: Evolent Health Director Acquires Shares
Statement of Changes in Beneficial Ownership
Evolent Health Director Craig A. Barbarosh acquired 41,096 shares of Class A Common Stock through restricted stock units.
Summary
- Craig A. Barbarosh, a Director at Evolent Health, Inc., acquired 41,096 shares of Class A Common Stock.
- The acquisition was made through restricted stock units granted under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
- These securities vest on June 4, 2027, or the date of the Company's 2027 annual meeting, contingent upon continued service.
- Following this transaction, Mr. Barbarosh beneficially owns 95,031 shares of Class A Common Stock.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard equity grant to a director, indicating continued engagement and alignment with company performance, rather than a significant new development.
Positives
- Director acquisition of shares can signal confidence in the company's future prospects.
- The acquisition of a significant number of shares (41,096) by a director indicates a long-term commitment.
Future Outlook
The restricted stock units vest on June 4, 2027, or the date of the Company's 2027 annual meeting, subject to continued service, indicating a forward-looking incentive tied to performance and tenure.
Industry Context
StockSavvy.ai notes that director stock acquisitions, particularly through equity grants like restricted stock units, are common within the healthcare technology sector as a means to align executive and director interests with those of shareholders and incentivize long-term value creation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Incentive Plan | Grant of restricted stock units to Director Craig A. Barbarosh under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. | 06/04/2026 | Reinforces alignment of director compensation with long-term company performance and shareholder value. |
Stakeholder Impact
- Shareholders: The acquisition by a director may be viewed positively as a sign of confidence in the company's future, potentially aligning director interests with shareholder value.
- Employees: The incentive plan under which the shares were granted is a standard component of executive and director compensation, designed to retain talent and motivate performance.
Next Steps
- Vesting of restricted stock units on June 4, 2027, or the date of the Company's 2027 annual meeting, subject to continued service.
Key Dates
| Date | Description |
|---|---|
| 06/04/2026 | Earliest transaction date and vesting commencement date for restricted stock units. |
| 06/08/2026 | Date of signature for the filing. |
| 06/04/2027 | Vesting date for restricted stock units, or the date of the Company's 2027 annual meeting, whichever is earlier. |
Keywords
Evolent Health, Form 4, Director, Stock Acquisition, Restricted Stock Units, Beneficial Ownership, Class A Common Stock, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.